T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy
Summary:
The NCI seeks parties interested in research co-development and/or licensing this library of TCRs targeting CDKN2A mutations.
Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease
Summary:
The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer’s disease.
La Protein as a Novel Regulator of Osteoclastogenesis
Summary:
NICHD seeks co-development partners and/or licensees for the further development of methods to target the La protein for the regulation of osteoclast fusion and osteoclastogenesis.
Nandrolone 17 Beta-Carbonates
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.
Therapeutics Against Pathogenic Coronaviruses
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking research co-development partners and/or licensees to further develop and commercialize PIKfyve phosphatidyl linositol kinase inhibitors for the treatment of pathogenic coronaviruses. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of this technology.
Enhanced Antigen Reactivity of Immune Cells Expressing a Mutant Non-Signaling CD3 Zeta Chain
Summary:
Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners to develop therapeutic cell populations arising out of these technologies. An ideal partner would enter into both a Cooperative Research and Development Agreement (CRADA) and an exclusive license agreement towards commercialization of one or more therapies to treat various oncologies.
T Cell Receptor Targeting CD22 for the Treatment of Lymphomas and Leukemias
Description of Technology:
CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface.
Camel VHH Nanobodies Bind the S2 Subunit of SARS-CoV-2 and Broadly Neutralize Variants including Omicron
Summary:
The NCI seeks research co-development partners and/or licensees to further develop this nanobody as a possible treatment of COVID-19 infections.
An Anti-Viral Polypeptide: Griffithsin
Summary:
Researchers at the NCI seek licensing and/or co-development research collaborations for anti-viral Griffithsin (GRFT) proteins.
Single Domain Antibodies (Nanobodies) Targeting SARS-CoV-2 for treating COVID-19
Summary:
The NCI seeks licensing and/or co-development research collaborations for SARS-CoV-2 targeting nanobodies.